Afatinib is a targeted therapy. afatinib is classified as a tyrosine kinase inhibitor- epidermal growth factor receptor (egfr) inhibitor.indications:- non-small cell lung cancer, metastatic, egfr mutation-positive: first-line treatment of metastatic non-small cell lung cancer (nsclc) in patients whose tumors have nonresistant epidermal growth factor receptor (egfr) mutations as detected by an approved test.limitations of use: safety and efficacy have not been established in patients whose tumors express resistant egfr mutations.- non-small cell lung cancer, metastatic squamous: treatment of previously treated metastatic squamous cell nsclc that has progressed following platinum-based chemotherapy.